-
Diagnostics World News | Elaine Gee is Principal Data Scientist at Mirvie, a company dedicated to using technology to improve maternal health and identify pregnancy complications early using blood-based RNA profiling.
Jan 28, 2022
-
Diagnostics World News | Researchers at Mount Sinai and the University of Colorado are pursuing the possibilities that stem from predicting which COVID-19 patients are most likely to deteriorate over time. The hope is that this ability could help health care professionals more effectively triage patients and pair them with appropriate treatments to improve outcomes.
Jan 27, 2022
-
Diagnostics World News | It has proven exceedingly difficult to identify reliable and reproducible genetic markers for depression, but it now appears possible to efficiently leverage a biochemical hallmark to create a blood test. The basis of the test is the four-decade-old discovery that depression is tied to low levels of the intracellular molecule adenylyl cyclase, made in response to neurotransmitters such as serotonin and epinephrine.
Jan 25, 2022
-
Diagnostics World | Researchers at the University of Michigan (U-M) have made the connection between cellular motility—with a known connection to tumor metastasis—and the shape-shifting behavior of cancer cells to become more “missile-like” and thus better able to make the voyage from one site in the body to another. The newly acquired characteristic arises when epithelial cells morph into mesenchymal cells, but the transition can’t be seen if the cells are all held hostage on a glass microscope slide.
Jan 19, 2022
-
Diagnostics World News | At the JP Morgan Healthcare Conference—being held virtually again this year—diagnostics companies gave overviews of their 2021 business and their views of the future. Here are the highlights we noted from presentations from Thermo Fisher Scientific, Abbott, and Natera.
Jan 17, 2022
-
Diagnostics World News | Mammography has a lot of well-recognized shortcomings among women with dense breasts as well as those diagnosed with breast cancer who need their response to therapy closely monitored. A cheaper, noninvasive, and easy-to-perform test is now under development that could solve for its clinical limitations and is on track to hit the market as early as 2023.
Jan 13, 2022